Spots Global Cancer Trial Database for Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
Official Title: A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme
Study ID: NCT00730262
Conditions
Interventions
Study Description
Brief Summary: The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sloan-Kettering Institute for Cancer Research, New York, New York, United States
Duke University, Durham, North Carolina, United States
Ottawa Health Research Institute, Ottawa, Ontario, Canada
The Pencer Brain Tumor Center, Princess Margaret Hospital, Toronto, Ontario, Canada
Hôpital Notre-Dame du CHUM, Montreal, Quebec, Canada
Royal Victoria Hospital, Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
L'Hotel-Dieu de Quebec, Quebec, , Canada
Contact Details
Name: Warren Mason, MD
Affiliation: The Pencer Brain Tumor Center, Princess Margaret Hospital, Toronto
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
